Method for potentiating an immune response with derivatives
US4994475A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Dec 19, 1989 |
| Grant date | Feb 19, 1991 |
| Priority date | — |
| Expiry date | Dec 19, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I ##STR1## wherein: R.sub.1 represents methoxy, ethoxy or hydroxy, PA0 R.sub.2 represents methoxy, ethoxy, hydroxy or hydrogen; PA0 each R.sub.3 independently represents methyl or ethyl; PA0 R.sub.4 represents hydrogen or methyl; PA0 R.sub.5 represents hydrogen or methyl; and PA0 n represents 2 or 3, and a pharmacologically acceptable acid addition salt thereof (a) have anxiolytic activity, (b) antagonize the anxiogenic activity of benzodiazepine inverse agonists, (c) reduce chronic abnormally high brain levels of serotonin or its metabolite 5-hydroxy-indoleacetic acid and (d) have antibacterial and antiviral activity. These activities are believed to be related to a reduction in serotonin turnover caused by blocking the depolarisation activation of tryptophan hydroxylase. Novel compositions comprise the compounds with a benzodiazepine agonist or benzodiazepine inverse agonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.